Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric IOL Implantation Compared to Monofocal IOL Implantation

Overview

The objectives of this study are to assess and compare bilateral uncorrected distance visual acuity and distance spectacle independence post bilateral implantation of AcrySof Toric Intraocular Lenses (IOLs) and monofocal IOLs. Secondary outcomes will include cost of eyeglass purchased and patient vision-related quality of life.

Full Title of Study: “Visual Outcomes After Bilateral Surgical Cataract Phacoemulsification: AcrySof Toric Intraocular Lens (IOL) Implantation Compared to Monofocal IOL Implantation”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Double (Participant, Outcomes Assessor)
  • Study Primary Completion Date: December 2010

Interventions

  • Device: Toric T3 – T9
    • Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
  • Device: Monofocal
    • Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.

Arms, Groups and Cohorts

  • Experimental: Toric T3 – T9
    • Bilateral implantation of a Toric intraocular lens (IOL) models T3, T4, T5, T6, T7, T8 or T9
  • Active Comparator: Monofocal
    • Bilateral implantation of a monofocal intraocular lens (IOL) model with no toric component.

Clinical Trial Outcome Measures

Primary Measures

  • Uncorrected Distance Visual Acuity
    • Time Frame: 6 Months After Surgery
    • Visual Acuity (VA) is measured in logMAR. LogMAR is the “logarithm of the minimum angle of resolution”. A lower logMAR value indicates better visual acuity.
  • Spectacle Independence
    • Time Frame: 6 Months After Surgery
    • Spectacle Independence (the ability of the patient to go without corrective lenses) measured by a subjective patient questionnaire.

Secondary Measures

  • Vision-related Quality of Life
    • Time Frame: 6 Months After Surgery
    • Vision related quality of life as measured by a subjective subject questionnaire.

Participating in This Clinical Trial

Inclusion Criteria

  • are willing and able to understand and sign an informed consent; – are willing and able to attend postoperative examinations per protocol schedule; – are ≥ 21 years of age, of either gender and any race; – have bilateral, age related, cataracts; – have planned cataract removal via phacoemulsification with implantation of an intraocular lens (IOL); – are available to undergo second eye surgery within 6 weeks of the first eye surgery; – are in good ocular health, with the exception of cataracts; – are free of disease(s)/condition(s) listed in the "Precautions" section of the AcrySof Toric and monofocal package inserts: choroidal hemorrhage, chronic severe uveitis, concomitant severe eye disease, extremely shallow anterior chamber, medically uncontrolled glaucoma, microphthalmos, non-age-related cataract, proliferative diabetic retinopathy (severe), severe corneal dystrophy, severe optic nerve atrophy, irregular corneal astigmatism and color vision deficiencies. – have regular corneal astigmatism; – qualify for bilateral AcrySof Toric IOLs on the AcrySof Toric Calculator (www.acrysoftoriccalculator.com) – are able to obtain pupil dilation ≥ 5.0 mm – are able to read and understand one of the following languages: Dutch, French, German Exclusion Criteria:

  • previous corneal surgery and/or reshaping – abnormality, disease and/or conditions of the cornea (i.e. keratoconus, corneal dystrophy, keratitis, corneal scar, etc.), which would clinically contra-indicate the implantation of a toric intraocular lens – planned multiple procedures during cataract/IOL implantation surgery – planned limbal relaxing incision (LRI), Excimer laser treatment or similar procedure prior to or during the course of the study – an ocular disease and/or condition that may compromise visual acuity levels (i.e. glaucoma, diabetic retinopathy, amblyopia, etc.) – pregnant, lactating or planning pregnancy during course of study. Subjects who become pregnant during the study will not be discontinued; however, data may be excluded from the effectiveness analyses because pregnancy can alter refraction and visual acuity results. Data will be collected on the CRF as observations.

Gender Eligibility: All

Minimum Age: 21 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Alcon Research
  • Provider of Information About this Clinical Study
    • Sponsor

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.